title: Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective.
abstract: Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.
authors.forename: M
authors.initials: M
authors.lastname: Petri
mesh_terms: D015331:Cohort Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology*